Feature | Breast Imaging | September 07, 2018 | By JoAnn Pushkin

Confused About Mammogram Screening Guidelines?

Given the disparity in mammography guidelines, it can be a challenge to explain why and what the most appropriate screening protocol is for a patient

Mammogram Guidelines for Dense breast tissue

Dense breast tissue categories include fatty, scattered fibroglandular density, heterogeneously dense and extremely dense.

JoAnn Pushkin

JoAnn Pushkin

comparison for breast screening guidelines and mammography guidelines

This chart shows a comparison for breast screening guidelines.

Breast cancer screening and mammography screening guidelines

Breast cancer screening guidelines, a comparison by mammography interval.

If you are confused about the conflicting advice surrounding mammography screening guidelines, welcome to the club. When should mammography screening begin? How often is screening necessary? When should screening end? The varying national breast screening guidelines may have both patients and health providers uncertain as to appropriate recommendations. As the screening guideline discussion is one which has found traction in the news and on social media, it may be a challenge to address a patient’s questions about why her own screening protocol differs from what she may be hearing.

In January 2016, and with much media attention, the U.S. Preventive Service Task Force (USPSTF) issued its final breast cancer screening recommendations. These recommendations differ from those of several national health organizations and have generated confusion and conflicting messaging on the topic within the public arena. Since the USPSTF final guidelines were issued — which recommend screening begin at age 50 and at two-year intervals — the American College of Radiology/Society of Breast Imaging (ACR/SBI), the American Cancer Society (ACS) and the American Congress of Obstetricians and Gynecologists (ACOG) have also updated their own recommendations.

To assist with an analysis of the guideline recommendations, DenseBreast-info.org developed the Breast Cancer Screening Guideline Comparison. Note that the ACS now recommends screening starting at age 45 with an option to start at 40, while ACOG recommends offering screening starting at age 40 but not later than 50. The ACR/SBI, American Medical Association (AMA) and National Comprehensive Cancer Network (NCCN) continue to recommend screening beginning at age 40 and continuing at an annual interval. The ACS suggests mammography interval annually for ages 45-54, and every one to two years at age 55 and older, while ACOG suggests every one to two years without age qualifiers.

The age to stop mammography also differs among guidelines and varies from a specific age cutoff (USPSTF suggests 74 years of age, ACOG suggests age 75 and then shared decision making), to stopping when life expectancy is less than 10 years (ACS), to no specified age limit with recommendation tailored to the individual patient’s health status (ACR/SBI). The AMA and NCCN do not state an age to stop mammography screening.

In light of the growing availability and utilization of 3-D mammography (also known as tomosynthesis), several guidelines also include their view on the technology’s benefits, and these also differ. The ACR/SBI, ACS and NCCN find it an “improvement” over 2-D mammography in terms of detection and recall. Because the USPSTF only considers data from randomized trials with mortality as an endpoint, and there are no such trials of any breast imaging other than mammography, USPSTF’s position is that there is still “insufficient evidence to support routine use.” The ACOG and the AMA do not state positions on 3-D.

Given the disparity in the guidelines, it can be a challenge to explain why and what the most appropriate screening protocol is for a patient. DenseBreast-info.org believes that patients should start their screening mammograms before age 45 for the following reasons:

• The entire reason we screen for breast cancer is to find it early, when most treatable and survivable.

• Breast cancer is the No. 1 cause of death in women aged 35 to 54 years.

• Mammography has been proven to reduce deaths due to breast cancer in women screened beginning at age 40.

• 25 percent of all years of life lost to breast cancer occur in women diagnosed before the age of 45.

• Women at “high risk” for breast cancer due to known or suspected disease-causing mutation (such as BRCA1 or BRCA2) should begin screening at least by age 30, to include magnetic resonance imaging (MRI).

 

The American College of Radiology also recommends annual MRI in addition to mammography in women determined to be at “higher than average risk,” which includes all women diagnosed with breast cancer at/by age 50 and women diagnosed at any age with a personal history of breast cancer and dense breasts.1

 

What about false positives?

• About 10 percent of women having a screening mammogram will be called back for extra testing or views. This is normal. Among women called back, 95 percent do not have cancer. If a needle biopsy is necessary, even that is a simple test.

• The newer technique of 3-D mammography (tomosynthesis) is better able to show cancer and results in fewer callbacks for extra testing.

 

What about screening in dense breasts?

• Younger women are more likely to have dense breast tissue, which can hide cancer on mammography.

• In women who have breasts categorized as “dense” (heterogeneously dense or extremely dense), adding screening ultrasound (if the woman is not a high risk) after a mammogram (2-D or 3-D) can help find more breast cancers. Because ultrasound detects more areas that need follow-up, there is more to check. Ultrasound also increases the chance of needing a needle biopsy to determine if something detected is cancerous or not.

 

Reference

1. Monticciolo DL et al. J Am Coll Radiol. 2018 Mar;15(3 Pt A):408-414.doi: 10.1016/j. jacr.2017.11.034. Epub 2018 Jan 19.

 

JoAnn Pushkin is executive director of DenseBreast-info, Inc. For more information on breast screening, risk factors and dense breasts, visit DenseBreast-info.org.

© DenseBreast-info Inc. and JoAnn Pushkin

Related Content

AI has the potential to help radiologists improve the efficiency and effectiveness of breast cancer imaging

Getty Images

Feature | Breast Imaging | May 28, 2020 | By January Lopez, M.D.
Headlines around the world the past several months declared that...
a Schematic of the system. The entire solid tumour is illuminated from four sides by a four-arm fibre bundle. A cylindrically focused linear array is designed to detect optoacoustic signals from the tumour. In vivo imaging is performed in conical scanning geometry by controlling the rotation and translation stages. The sensing part of the transducer array and the tumour are submerged in water to provide acoustic coupling. b Maximum intensity projections of the optoacoustic reconstruction of a phantom of pol

a Schematic of the system. The entire solid tumour is illuminated from four sides by a four-arm fibre bundle. A cylindrically focused linear array is designed to detect optoacoustic signals from the tumour. In vivo imaging is performed in conical scanning geometry by controlling the rotation and translation stages. The sensing part of the transducer array and the tumour are submerged in water to provide acoustic coupling. b Maximum intensity projections of the optoacoustic reconstruction of a phantom of polyethylene microspheres (diameter, 20 μm) dispersed in agar. The inset shows a zoomed-in view of the region boxed with a yellow dashed line. In addition, the yellow boxes are signal profiles along the xy and z axes across the microsphere centre, as well as the corresponding full width at half-maximum values. c Normalized absorption spectra of Hb, HbO2 and gold nanoparticles (AuNPs). The spectrum for the AuNPs was obtained using a USB4000 spectrometer (Ocean Optics, Dunedin, FL, USA), while the spectra for Hb and HbO2 were taken from http://omlc.org/spectra/haemoglobin/index.html. The vertical dashed lines indicate the five wavelengths used to stimulate the three absorbers: 710, 750, 780, 810 and 850 nm. Optoacoustic signals were filtered into a low-frequency band (red) and high-frequency band (green), which were used to reconstruct separate images.

News | Breast Imaging | May 26, 2020
May 26, 2020 — Breast cancer is the most common cancer in women.
Phone call and linkage-to-care-based intervention increases mammography uptake among primary care patients at an urban safety-net hospital

Getty Images

News | Mammography | May 22, 2020
May 22, 2020 — Telephone outreach coupled with scheduling assistance significantly increased...
The Breast Imaging and Reporting System (BI-RADS) was established by the American College of Radiology to help classify findings on mammography. Findings are classified based on the risk of breast cancer, with a BI-RADS 2 lesion being benign, or not cancerous, and BI-RADS 6 representing a lesion that is biopsy-proven to be malignant.

Getty Images

News | Breast Imaging | May 19, 2020
May 19, 2020 — Women with mammographically detected breast lesions that are probably benign should have follow-up sur
Podcast: Impact of COVID-19 on Breast Cancer Treatment with Dr. Andrea Madrigrano

Kubtec hosts a Podcast: Impact of COVID-19 on Breast Cancer Treatment with Andrea Madrigrano, M.D., as part of its public service campaign.

News | Coronavirus (COVID-19) | May 06, 2020
May 6, 2020 — The COVID-19 pandemic is an unprec
The American Society of Breast Surgeons (ASBrS), the National Accreditation Program for Breast Centers (NAPBC), the National Comprehensive Cancer Network (NCCN), the Commission on Cancer (CoC) of the American College of Surgeons, and the American College of Radiology (ACR) have released new joint recommendations for prioritization, treatment and triage of breast cancer patients during the coronavirus (COVID-19) pandemic

Getty Images

News | Breast Imaging | April 13, 2020
April 13, 2020 — The American Society of Breast Surgeons (...
Table 1. Compared to 2-D mammography, which yields four images per patient, digital breast tomosynthesis (DBT), or 3-D mammography, produces hundreds of images per patient. While this provides more information for clinicians, the exponential increase in data can result in reader fatigue and burnout, which may ultimately affect patient care.

Table 1. Compared to 2-D mammography, which yields four images per patient, digital breast tomosynthesis (DBT), or 3-D mammography, produces hundreds of images per patient. While this provides more information for clinicians, the exponential increase in data can result in reader fatigue and burnout, which may ultimately affect patient care.

Sponsored Content | Case Study | Artificial Intelligence | April 09, 2020
As the largest independent imaging group in Michigan with 10 locations across the state,...
Figure 1. R MLO view from four different years. The skin mole is marked with a circular skin marker (TomoSPOT REF# 782, Beekley Medical) on the far-left image. These images demonstrate the potential for significant variability in location of the skin lesion due to movability of the skin during positioning.

Figure 1. R MLO view from four different years. The skin mole is marked with a circular skin marker (TomoSPOT REF# 782, Beekley Medical) on the far-left image. These images demonstrate the potential for significant variability in location of the skin lesion due to movability of the skin during positioning. 

Sponsored Content | Case Study | Breast Imaging | April 09, 2020
Christina Jacobs, M.D., Director of Breast Imaging (...